Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT04469569

Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors

Conditions: Papillomavirus Vaccines

Sex: All
Ages: 9 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 8120
Sponsor: University of Alabama at Birmingham

Location: University of Alabama at Birmingham Birmingham Alabama

Summary

The focus of this research is on increasing the uptake of the human papillomavirus (HPV) vaccine in young cancer survivors, a vulnerable population at high risk for developing new cancers (such as cervical and anal cancer) caused by persistent HPV infection. An effective vaccine exists that can prevent these cancers, but HPV vaccine uptake is low among young cancer survivors. This research will evaluate the effectiveness and implementation of an evidence-based intervention, adapted for use by healthcare providers in pediatric oncology clinics, to increase the uptake of HPV vaccine among young cancer survivors 9-17 years of age. Results of this research will provide important information that can be used to implement new strategies to increase the uptake of the HPV vaccine among young cancer survivors.

Eligibility Criteria

Inclusion Criteria: 1. HEALTHCARE PROVIDERS (ONCOLOGISTS, ADVANCED PRACTICE PROVIDERS) * ≥18y of age * Care for cancer survivors seen in the targeted clinic who are age 9-17y, ≥1y off-therapy, and reside in the state where clinic is located * Licensed to order vaccines * Willing to complete surveys and/or interviews 2. CHILDHOOD CANCER SURVIVORS * 9-17y of age * ≥1y following completion of cancer therapy * Reside in the state where clinic is located * Receive follow-up care (in person or via telehealth) at the participating sites Exclusion Criteria: N/A

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04469569). StuddyBuddy aggregates publicly available trial information.